BMJ Open Integrating a brief mental health intervention into primary care services for patients with HIV and diabetes in South Africa: study protocol for a trial-based economic evaluation

Vimbayi Mutyambizi-Mafunda,¹ Bronwyn Myers,² Katherine Sorsdahl,³ Crick Lund,^{3,4} Tracey Naledi,^{5,6} Susan Cleary⁷

To cite: Mutyambizi-Mafunda V, Myers B, Sorsdahl K, *et al.* Integrating a brief mental health intervention into primary care services for patients with HIV and diabetes in South Africa: study protocol for a trial-based economic evaluation. *BMJ Open* 2019;**9**:e026973. doi:10.1136/bmjopen-2018-026973

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-026973>).

Received 28 September 2018

Revised 11 March 2019

Accepted 15 April 2019

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Ms. Vimbayi Mutyambizi-Mafunda;
vimbayi.mafunda@uct.ac.za

ABSTRACT

Introduction Depression and alcohol use disorders are international public health priorities for which there is a substantial treatment gap. Brief mental health interventions delivered by lay health workers in primary care services may reduce this gap. There is limited economic evidence assessing the cost-effectiveness of such interventions in low-income and middle-income countries. This paper describes the proposed economic evaluation of a health systems intervention testing the effectiveness, cost-effectiveness and cost-utility of two task-sharing approaches to integrating services for common mental disorders with HIV and diabetes primary care services.

Methods and analysis This evaluation will be conducted as part of a three-armed cluster randomised controlled trial of clinical effectiveness. Trial clinical outcome measures will include primary outcomes for risk of depression and alcohol use, and secondary outcomes for risk of chronic disease (HIV and diabetes) treatment failure. The cost-effectiveness analysis will evaluate cost per unit change in Alcohol Use Disorder Identification Test and Centre for Epidemiological Studies scale on Depression scores as well as cost per unit change in HIV RNA viral load and haemoglobin A1c, producing results of provider and patient cost per patient year for each study arm and chronic disease. The cost utility analyses will provide results of cost per quality-adjusted life year gained. Additional analyses relevant for implementation including budget impact analyses will be conducted to inform the development of a business case for scaling up the country's investment in mental health services.

Ethics and dissemination The Western Cape Department of Health (WCDoH) (WC2016_RP6_9), the South African Medical Research Council (EC 004-2/2015), the University of Cape Town (089/2015) and Oxford University (OxTREC 2-17) provided ethical approval for this study. Results dissemination will include policy briefs, social media, peer-reviewed papers, a policy dialogue workshop and press briefings.

Trial registration number PACTR201610001825405.

Strengths and limitations of this study

- This study will provide some of the first empirical evidence of the cost-effectiveness of integrating services for common mental disorders in the primary care offering for HIV and diabetes.
- The study will generate findings that may guide priority setting through application of quality-adjusted life year-based outcomes and decision-making around the implementation of mental health counselling within the health system.
- This paper adds to the growing body of protocols for economic evaluations conducted alongside randomised controlled trials.
- As health service use is self-reported, there is a possibility for recall bias, to limit this, a 1-month recall period will be used for ambulatory services and a 6-month recall for hospitalisation, and hospitalisations will be validated through the Department of Health Data Centre.
- The 1-year follow-up period may reflect outcomes that do not fully represent the full benefit that patients and the health system could gain through the availability of this service; further work using an extended follow-up period may be proposed.

INTRODUCTION

Common mental disorders (CMDs) including depression, anxiety and alcohol use disorders are highly prevalent conditions that impose a significant societal cost and impact on quality of life.¹ Globally, these conditions have been shown to be the leading cause of non-fatal burden of disease.^{1 2} The disabling impact of these conditions is particularly significant in patients suffering from chronic physical conditions.³ CMD comorbidity has been shown to exacerbate major modifiable risk factors for chronic disease; contribute to chronic disease progression; increase the prevalence of preventable complications and

disability; result in poor adherence and ultimately lead to treatment failure.^{1 4} There is a plethora of evidence on the impact of depression and alcohol use disorders on diabetes outcomes.^{5 6} Likewise, alcohol consumption and depressive conditions have been associated with poor HIV outcomes.^{7 8} In addition, high-income country (HIC) evidence suggests that patients with these multimorbidities have higher healthcare costs even after adjusting for the costs of mental healthcare⁹; suggesting potential cost savings from investing in mental health treatment for patients with multimorbidities.¹⁰

There is a pressing need for evidence on cost-effective strategies for integrating mental healthcare into primary health services, particularly in low-income and middle-income countries (LMICs), where health systems are typically fragile and chronically underfunded. In these health systems, an investment in mental health services at primary care level for patients with chronic disease has the potential to result in significant returns on investment due to reduced chronic disease treatment costs. South Africa—with the world's largest ART programme,¹¹ an increasing prevalence of diabetes¹¹ and a huge unmet need for CMD treatment¹²—is one LMIC that may benefit from this integrated approach.

Task-sharing^{13 14} involves redistributing tasks from specialist providers to non-specialist health workers,¹⁵ with specialists providing ongoing support to these health workers. Task-sharing is a common strategy for the provision of primary care services in constrained LMIC settings.¹⁶ Due to the long lead times in training mental health staff and financial resource limitations, the task-sharing discourse has found appeal in the policy discussions around introducing and expanding mental healthcare in LMICs.^{1 17} These discussions are centred on using task-shared approaches¹⁸ to upskill lay health workers to integrate mental health services such as brief counselling interventions into primary care.^{19 20} Task-sharing the psychosocial counselling of patients who have chronic comorbidities to lay health workers is a particularly appealing and potentially cost-effective strategy to treat patients and support their adherence to chronic medication^{21 22} and therefore limit overall health system costs of care.^{4 16}

While task-sharing the treatment for CMDs from mental health professionals to lower level healthcare workers has been suggested as an effective way to deliver services within the context of scarce human resources⁴ and has been shown to be cost-effective in some HIC settings, there is little if any economic evidence to support the implementation of such strategies in LMICs.^{4 16} This lack of evidence limits decision making around the allocation of resources for these services. Economic evidence on the institutional investment, cost-effectiveness and budget impact of this approach is necessary for empirically informed health service planning.²³ This work presents a protocol of a cost-effectiveness (CEA) and cost-utility analysis (CUA) from a societal perspective (ie, providers and patients) of a task-shared mental health

counselling intervention for patients with comorbid HIV or diabetes in South Africa.

METHODS AND ANALYSIS

Patient and public involvement

Patients and the public were engaged with through the trial, and were not directly involved in this study.

Trial design

This study is nested in Project MIND, a cluster randomised controlled trial across 24 public primary care facilities.²⁴ Myers *et al*²⁴ describe the trial in detail. The trial will compare the effectiveness of treatment as usual (MIND_TAU) and two alternative methods for integrating a psychosocial intervention into the primary care services for HIV and diabetes. Treatment as usual (TAU) is representative of typical primary care level services for CMD in the South African public health service facilities, which is typically limited to referrals.^{25 26} The two models will be the dedicated and designated models of care. In the dedicated approach (MIND_DED), community health workers (CHWs) will be hired and added to the facility staff complement and will dedicate their time to *only* delivering the new counselling service. In the designated approach (MIND_DES), CHWs already working in the facility will be designated to deliver the service *in addition* to their other chronic disease-related activities such as adherence counselling for HIV and health promotion. Supervision and debriefing of all the counsellors in the active arms will be task-shifted to registered psychological counsellors in line with the national mental health policy framework.²⁷ Descriptions of the CHWs and registered psychological counsellors roles in the MIND-DED and MIND-DES models and their qualifications and skills levels are detailed in the trial protocol.²⁴

Intervention and comparator

The counselling programme delivered in MIND-DED and MIND-DES is based on motivational interviewing (MI) and problem solving therapy (PST).²⁸ It is delivered in three sessions over 6 weeks with one optional booster session. The MI component provides psychoeducation about depression and hazardous alcohol use in relation to chronic disease, builds readiness for counselling and helps participants develop goals for counselling. The PST component targets maladaptive coping strategies and builds skills and strategies for dealing with life problems. Patients will receive individual face-to-face counselling from CHWs and take-home booklets to support self-learning between sessions. Registered psychological counsellors, supervised by psychologists, will train the counsellors.²⁴ The underlying theory, content and evidence for the efficacy of the counselling approach for reducing symptoms of depression and hazardous/harmful alcohol use over the 1-year time frame have been described previously.^{29–31} In the TAU arm, the standard package of care will be provided to patients who are

suspected of having mental health problems. In general, patients using the HIV or diabetes service are asked by a nurse or doctor attending to their care about their mental well-being, life stressors and use of alcohol or other substances. Patients are provided with advice to change their lifestyles. Where the healthcare provider deems it necessary, patients are referred to a mental health nurse for further assessment or screening. The patient may also be referred to a social worker who may refer them to non-governmental organisations (NGOs) who provide counselling and support services.²⁴

Outcome measures

The primary outcomes for the trial are measures of psychosocial functioning, specifically changes in self-reported risk of depression as measured by the Centre for Epidemiological Studies scale on Depression (CES-D)³² and self-reported hazardous alcohol use as measured by the Alcohol Use Disorder Identification Test (AUDIT).³³ Secondary outcomes include biological measures aimed at assessing changes in chronic disease treatment response, specifically haemoglobin A1c (HbA1c) for diabetes and HIV-1 RNA viral loads for HIV. Other secondary outcome measures include self-reported adherence to chronic disease medication and health-related quality of life (HRQoL) measured using the EuroQol-5D (EQ-5D).³⁴ All outcomes are measured longitudinally at baseline, and at 6 and 12 months follow-up assessments, recruitment on the trial started in 2017 and will end in February 2019 and final outcome assessments will end in 2020 (figure 1).

Sample size and patient population

Recruitment will be restricted to consenting adult patients who meet criteria for hazardous alcohol use or depression using the AUDIT or CES-D. These patients are already diagnosed and receiving treatment for diabetes or HIV, but not currently receiving treatment for a CMD. The trial requires a sample size of 1200 patients (600 with HIV and 600 with diabetes) to detect reductions in hazardous alcohol use and risk of depression at 12-month follow-up. The sample size calculations are based on a cluster randomised design with two active arms and a control arm. This clinical trial is powered to detect clinical outcomes, specifically reductions hazardous/harmful alcohol use and risk of depression at 12-month follow-up rather than economic outcomes.^{24 35}

MIND economic evaluation

Objective

The study will be a prospective economic evaluation. The objectives include estimating:

- Full economic provider costs of the mental health intervention; any cost offsets attributable to the intervention related to changes to the costs of HIV or diabetes care at the primary care level and changes to the costs of referral care (including tuberculosis (TB), emergency department and inpatient care).
- Patient costs: associated with the intervention which will include direct out-of-pocket payments to private health providers (consultations and medications, etc), travel and subsistence costs and productivity losses.

Analysis	Assessment/ Economic Evaluation Outcomes	Measurement instrument OR Clinical Parameter	Assessment Timing (Trial recruitment: starts 2017- ends 2019)		
			Baseline	6 months	1 Year
CEA	1° Outcomes				
	Harmful alcohol use (Self-report interview)	AUDIT	✓	✓	✓
	Depression (Self-report interview)	CES-D	✓	✓	✓
	2° Outcomes				
	Diabetes treatment failure risk	HbA1c	✓	✓	✓
		BMI			
	HIV treatment failure risk	HIV-1 RNA (HIV-viral load)	✓	✓	✓
CUA	Chronic Disease Medication Adherence	Visual analogue Scale and CASE adherence Index	✓	✓	✓
	Multi-attribute Outcomes				
	QALY	EQ-5D	✓	✓	✓

Figure 1 Economic evaluation: analyses, outcomes, measurement and assessment timing. AUDIT, Alcohol Use Disorder Identification Test; BMI, body mass index; CEA, cost-effectiveness analysis; CES-D, Centre for Epidemiological Studies scale on Depression; CUA, cost- utility analysis; EQ-5D, EuroQol-5D; HbA1c, haemoglobin A1c; QALY, quality-adjusted life year.

- iii. Cost-effectiveness in terms of the incremental cost per unit of improvement in disease-specific outcome (CES-D, AUDIT, HIV-1 RNA, HbA1c).
- iv. Cost-utility in terms of the incremental cost per quality-adjusted life year (QALY) gained.
- v. Budget impact of scaling up the intervention.

To achieve these objectives, the incremental cost-effectiveness ratio (ICER) will be calculated by ordering the MIND_DED, the MIND_DES and MIND_TAU alternatives from least cost to highest cost and calculating the difference in costs and outcomes against the next less costly, non-dominated alternative or against the common baseline of MIND_TAU.

Perspective

The aim of the economic evaluation is to inform health service decision makers about the costs, outcomes, economic efficiencies and budget impact of introducing task-shared psychosocial counselling to their chronic disease patient body in a resource-scarce context. As such, the economic evaluation will be conducted from a provider perspective, reflecting health service budget constraints. In line with good practice recommendations, the analyses will also be presented from a societal perspective (including both provider and patient perspectives). While public sector primary healthcare is free at the point of use, patients incur time and travel costs when accessing care and may experience productivity losses; in addition, they may incur costs when using private sector health services. These costs will be collected to inform the patient perspective within the economic evaluation.

Time horizon and discount rate

As the health consequences of the intervention will be experienced over a period extending longer than 1 year, a discount rate will be applied to reflect differentials in timing.³⁶ A 3% discount rate will be used for discounting both costs and outcomes to allow comparability with other CEAs.³⁷

Estimating intervention effects

Single study-based estimates of clinical effectiveness will be obtained from the trial, which will provide the primary and secondary outcome measures previously described. In addition to the disease-specific primary outcomes, and the secondary HIV and diabetes outcomes which will be applied in the CEA, the QALY will also be calculated as an end point that will be used in the CUA. The ICER resulting when using a QALY measure represents the additional cost associated with accruing another QALY as one compares strategies (ie, the incremental cost per QALY gained). The QALY allows comparison of ICERs across different diseases and interventions.³⁷ QALYs are calculated by multiplying the length of time in a health state by the HRQoL of the health state. The EQ-5D is the most widely used instrument for measuring HRQoL for CUAs.³⁴ In South Africa, it has been validated and translated into Afrikaans and isiXhosa, two of the country's

official languages.³⁸ The EQ-5D is a self-assessment of health status across five domains which include mobility, self-care, usual activities, pain and discomfort and anxiety/depression.³⁹ In this study, the EQ-5D-3L³⁴ will be used to measure HRQoL. A single summary index score will be generated using preference weights derived from a time trade-off (TTO)-based valuation survey conducted in Zimbabwe in addition to the commonly used UK value set; the TTO is the most common valuation technique used in LMICs.⁴⁰ As the EQ-5D will be administered at all the assessment intervals (baseline, 6 months and 12 months post-enrolment), there will be three observations of the EQ-5D scores for each patient in the trial. The QALY gained per patient over the trial period will be calculated by measuring the area under the quality of life curve.³⁷

Estimating costs for the provider's perspective

Within economic evaluation, the appropriate scope of provider costs includes all costs incurred within the intervention and any changes in broader health system costs that can be attributable to the intervention. We have categorised these costs as intervention costs, HIV and diabetes service costs and other related provider costs. As shown in [table 1](#), our approach to estimating these costs entails the measurement of quantities of resources that are used, and multiplying these quantities by the value (or unit cost) of each resource. These separate steps of measurement and valuation are described below.

Measurement of resource use

For the intervention costs, an ingredients approach will be used to estimate resources. Routine data linked to intervention protocols will be collected and used to assess resources directly consumed in the provision of the intervention, including supplies, manuals and patient education materials. Facility observations of intervention delivery will be conducted for the economist to understand the intervention and the facility context; these observations will complement intervention cost data collection. The costs of intervention focused counsellor training and facility-level institutional strengthening and capacity development through organisational readiness workshops⁴¹ will be included in the cost analysis as start-up costs⁴² in order to capture the full economic costs of integrating the intervention into the primary care service for patients with chronic disease.⁴²

A time and motion tool (TMT) developed for this evaluation will measure counsellor time usage in delivering the intervention for both active arms in the study. Time tools have been used in analysis of human resource requirements for expanding access to HIV⁴³ and TB care⁴⁴ using lay health workers and have proved useful in highlighting the scope of duties of this cadre. To our knowledge, there is limited evidence in the South African context on time costs of CHW-delivered mental health counselling. The TMT will enable an analysis of differences in counsellor time usage in the different intervention modalities,

Table 1 Measuring and valuing provider costs

Cost component	Measurement		Valuation	
	Resources used	Quantities or utilisation	Valuation data	Allocation factor
Intervention				
Capital costs				
Facility readiness workshops	Number of staff	Time from trial data	Cost of employment converted to annual equivalent cost	DED/DES/TAU headcount
Intervention training for counsellors	Number of counsellors	Time from trial data	Cost of employment converted to annual equivalent cost	DED/DES/TAU headcount
Counselling room	Space	Square metres	Replacement value converted to annual equivalent cost	DED/DES/TAU headcount
Furniture and equipment	Tape recorders	Inventory	Replacement value converted to annual equivalent cost	DED/DES/TAU headcount
Vehicles	Vehicles	Inventory	Replacement value converted to annual equivalent cost	DED/DES/TAU headcount
Recurrent costs				
Counselling personnel	Number of staff (lay counsellors; registered counsellors; clinical psychologist)	Time from time and motion tool	Cost of employment×proportion of time	DED/DES/TAU headcount
Counselling supplies	Manuals, notebooks, pens	Number used—from trial data	Market value	DED/DES/TAU headcount
Non-intervention personnel	Number of staff	Time from facility data	Cost of employment×proportion of time	Facility headcount
Utilities	Electricity, water, other utilities, phone, cleaning, transport and stationery	Facility utilisation	Annual facility expenditure	Facility headcount
HIV/Diabetes service				
Capital costs				
Buildings	Space used for HIV/diabetes service	Square meters	Replacement value converted to annual equivalent cost	HIV/Diabetes headcount
Equipment and furniture	Equipment and furniture used for HIV/diabetes service	Inventory	Replacement value converted to annual equivalent cost	HIV/Diabetes headcount
Vehicles	Vehicles used for HIV/diabetes service	Inventory	Replacement value converted to annual equivalent cost	HIV/Diabetes headcount
Recurrent costs				
HIV/Diabetes personnel	Number of staff and staff time spent on HIV/diabetes service	Time from facility data	Cost of employment ×proportion of time	HIV/Diabetes headcount
Drugs	ARV/Diabetes medication	Treatment protocol	National tender prices	Direct allocation
Diagnostic tests	CD4 test, diabetes monitoring tests, etc	Treatment protocol	National Health Laboratory Service prices	Direct allocation
Non-HIV/diabetes personnel	Managerial, cleaning and security staff	Facility utilisation	Facility expenditure	Facility headcount

Continued

Table 1 Continued

Cost component	Measurement		Valuation	
	Resources used	Quantities or utilisation	Valuation data	Allocation factor
Building operating and maintenance	Electricity, water, other utilities, phone, cleaning, transport and stationery	Facility utilisation	Facility expenditure	Facility headcount
Other related healthcare providers				
Public clinic visit	Average cost per visit	Patient interviews	Facility expenditure	Facility headcount
Public hospital ER/OPD visit	Average cost per OPD visit	Patient interviews	Facility expenditure	Facility Inpatient days and Outpatient headcount
Public hospital inpatient day	Average cost per inpatient day	Patient interviews	Facility expenditure	Facility Inpatient days and Outpatient headcount

indicating opportunities for scale and scope efficiencies. It is anticipated that the costs associated with the TAU option will be minimal and any referral costs will be captured through patient self-report of services they have used.

For the HIV and diabetes services, a step-down methodology will be used to establish resource use. Staff time will be determined through review of facility organograms and interviews with senior managers. In addition, utilisation of HIV and diabetes medicine and diagnostics will be estimated by applying standard treatment guidelines/protocols for HIV and diabetes treatment in primary care services to utilisation statistics obtained from facility records (ie, protocol-based facility utilisation statistics).

Establishing the use of referral services is challenging given that there is no health information system that enables patient pathways through care to be established. Therefore, to establish patient utilisation of health services beyond their HIV and diabetes care at the primary level, we will administer a patient questionnaire developed for the study at baseline, and at the 6-month and 12-month assessments. Using this questionnaire, we will capture health service utilisation for other primary care services (eg, TB treatment), hospital services, emergency department care, paramedic care and referrals to mental health providers. Patients will be asked to quantify the number of these additional visits, and lengths of stay in hospital. Given concerns with patient recall, we have asked patients to estimate their usage of ambulatory services over the previous month and have used a recall period of 6 months for inpatient services. These data will then be extrapolated to estimate costs over the time horizon.

Valuation of costs

Once the utilisation of services has been established, we will estimate the unit cost of each service. This involves sourcing a value for each item (eg, annual cost of employment multiplied by proportion of time spent), as well as an allocation factor (eg, annual facility headcount) allowing the estimation of a unit cost (cost of

employment $\times$ proportion of time/headcount). These sources of data and allocation factors are outlined in detail in table 1.

For capital items, costs will be estimated using the replacement value method.³⁷ In essence, the current replacement value of each item is calculated and annuitized using data on the estimated useful life of the item and an interest rate representing the opportunity cost component for capital, in order to estimate an equivalent annual cost. An estimated useful life of between 5– and 20 years for furniture and buildings will be applied as while an interest rate of 8% will be used as the annuitization factor based on the rate of return on government bonds in South Africa.³⁷

Estimating costs for the patient perspective

Measurement of resource use

For the patient perspective, we will use a questionnaire at baseline, 6 and 12 months to estimate resource use. This will capture any user fees associated with public, private or NGO-provided health services as well as traditional and faith-based therapies. In addition, we will ask patients to estimate their time spent accessing healthcare services, as well as out-of-pocket payments for transport, subsistence and accommodation. Travel, subsistence and accommodation costs will relate to both the patient and their caregiver, if the patient is accompanied by a caregiver to any of these services.

Valuation of costs

Travel, subsistence and accommodation costs will be estimated using the out-of-pocket payments reported by patients. Time spent receiving healthcare will be valued using the equality of wages approach.^{45 46} We will apply this method as public health services in South Africa are typically accessed by those who have a lower socioeconomic status. Using this technique, the time costs for all patients are valued at the average income reported by the survey population.⁴⁵ This approach is expected to provide a relatively accurate reflection of the opportunity cost of

Figure 2 Project MIND: intervention arms, costs, outcomes and economic evaluation. HbA1c, haemoglobin A1c; OOP, out-of-pocket; TAU, treatment as usual.

unpaid labour and is favoured over the minimum wage approach in this context as a large proportion of the patients are unemployed resulting in a possible overestimate of the value of the time loss if the minimum wage is used.⁴⁵ In addition, we will ask patients if they have lost any income through seeking healthcare.

Figure 2 summarises the intervention arms, costs and outcomes that will be included in this study.

All costs will be valued at 2017/2018 prices and, to allow comparability with other studies will be converted from South African Rand (ZAR) to US\$, using appropriate conversion rates for the same period obtained from OANDA, an online currency exchange rate conversion site. Costs incurred during earlier periods (such as manual development) will be inflated using the Consumer Price Index to reflect 2017/2018 prices.

Analyses

Statistical analysis of costs and effects

Mean provider costs and patient costs will be calculated from baseline until the end of the intervention period. In addition, we will explore the extrapolation of costs to later periods if data allow for this. Cost differences between the MIND-TAU, and the MIND-DES and MIND-DED alternatives will be calculated. Sampling uncertainty for cost data will be estimated using statistical methods that account for the non-normal distribution of costs. Effect in terms of CES-D, AUDIT, HIV viral load, HbA1c and the QALY will be analysed using linear regression on intervention type.

Determining cost-effectiveness

The analysis will be conducted in line with the Consolidated Health Economic Evaluation Reporting Standards guidelines.⁴⁷ Decision analytical models³⁷ integrating the

cost and outcomes of the different intervention alternatives will be developed to assess cost-effectiveness. As a meaningful impact of the MIND-DES and MIND-DED on both costs and effects is anticipated, ICERs will be estimated in terms of incremental cost per natural unit and/or intermediate outcome for the CEA, and incremental cost per QALY gained for the CUA. As the trial is focused on health systems strengthening for the delivery of mental health services, the decision rule applies to maximising health within the healthcare budget constraint. Therefore, ICERs will be calculated from the provider perspective and, the cost per QALY gained will be compared with the cost-effectiveness thresholds (CETs) for LMIC settings.⁴⁸ If our intervention's ICER is less than the chosen CET, this will mean that diverting resources to the intervention will increase population health, and if the ICER is more than the CET the intervention is not cost-effective. Patient costs will be collected and reported on separately. In addition, to satisfy the requirements of common guidelines⁴⁷ and to allow for some degree of comparability with other studies, the ICERs will also be presented for the societal perspective, that is, including both provider and patient costs.

Sensitivity analyses

The decision analytical models will allow for univariate and multivariate sensitivity analyses to be conducted. This will enable the robustness of study findings to be tested by varying key parameters such as utilisation rates and assessing the impact on cost-effectiveness results. Standard areas of analytical focus will be considered, including testing sensitivity around the resource cost and prices, and theoretical controversies,⁴⁹ for example, TTO weights⁵⁰ and discounting of outcomes.³⁶ Further

Table 2 Planned sensitivity analyses

	Base case	Range
Simple sensitivity analysis		
Discount rate	3%	0%–10%
QALYs: HRQoL weights	EQ-5D valued using UK TTO	EQ-5D valued using Zimbabwe TTO
Unit costs	Primary data and data from published sources and official statistics for South Africa	Varied within plausible ranges as determined from a literature review of South African cost studies
Missing data	Multiple imputation	Complete case analysis
Probabilistic sensitivity analysis		
Intervention utilisation data	Mean value	95% uncertainty interval
Referral service utilisation data	Mean value	95% uncertainty interval
EQ-5D/CES-D/AUDIT data	Mean value	95% uncertainty interval
Clinical outcomes (HbA1c, HIV-1 RNA)	Mean value	95% uncertainty interval

AUDIT, Alcohol Use Disorder Identification Test; CES-D, Centre for Epidemiological Studies scale on Depression; EQ-5D, EuroQol-5D; HbA1c, haemoglobin A1c; HRQoL, health-related quality of life; QALY, quality-adjusted life year; TTO, time trade-off.

analyses to inform the economics of task-sharing will include sensitivity analysis focused on economies and diseconomies of scale and scope, using detailed data from the TMT.⁵¹ This will include testing variations in staff hours worked, variations in staff mix, lay counsellor funding models and infrastructure investments. The impact of intervention dosage on outcomes will also be assessed in the sensitivity analyses. Statistical methods including multiple imputation will be used to manage the effect of missing information on costs and effects.⁵² These sensitivity analyses are summarised in [table 2](#). Probabilistic sensitivity analysis (which allows application of CIs to point estimates) will be used for sensitivity analyses of all relevant individual-level variables. The sensitivity analyses will be used to produce a cost-effectiveness acceptability curve.

Budget impact analysis

There is an increased demand from decision makers in both LMIC and HIC settings for estimates of the real fiscal implications of investing in health services within a defined budget and budgetary period.^{53 54} Trial-based estimates of intervention uptake and population-based estimates of numbers in need of the intervention will be used in budget impact approximations,⁵⁵ which will be conducted using a mathematical programming approach.^{56 57} Mathematical programming provides a useful equity lens for informing policy decisions around the provision of care in high burden, high cost contexts.⁵⁸ It will involve analysing alternative implementation strategies with differing equity implications subject to a budget constraint. This approach aims to support policy making by applying principles of constrained maximisation in resource allocation.⁵⁸ The estimates from this study will inform policy-level discussions on the fiscal implications of investing in primary care mental health services.

ETHICS AND DISSEMINATION

In the CEA we foresee minimal risks to participants, as patient level data will be collected through the main trial, where, in order to minimise the risk of improper disclosure of information study staff will be required to sign a staff confidentiality agreement and will be trained and certified in protecting human participants. Data collection for the trial will be conducted using Computer-Assisted Personal Interviewing (CAPI) in which only a unique study identifier is used. Knowledge translation will be through policy briefs, and social media as well as peer-reviewed papers, and presentations at health economics and mental health policy conferences. Engagement with department of health policy makers and other key stakeholders will be through a policy dialogue workshop linked to the main trial's Stake Holder Advisory Group. Dissemination of results to the public will be through press briefings in national and local media.

DISCUSSION

The delivery of psychotherapy using varying models of task-sharing to less specialised health workers in primary care has been shown to be cost-effective in HIC settings across a range of mental health conditions^{59–61} but has limited empirical economic evidence in LMICs.^{51 62 63} This study will provide evidence to address this gap. Through the CEA, the relative efficiency of each delivery mechanism will be established, enabling a discussion around which model produces the best outcomes given the available resources. As staff time is expected to be one of the main drivers of costs due to the nature of the intervention, we have developed a time tool that will allow us to directly measure staff time usage and investigate any potential excess capacity (hypothesized to occur with the MIND-DED counsellors), and scope economies

(hypothesized to occur with the MIND-DES counselors), which would impact the comparative efficiency of the different alternatives and thus the cost-effectiveness results, as suggested in a similar study.⁵¹ The CUA will aid health service planners in their decision making around resource allocation and may be useful for guiding priority setting decisions both within the mental health budget space and across competing health priorities. To further support policy maker decisions, the affordability of implementing the intervention will need to be assessed, this will require further analysis using trial-based evidence on intervention uptake and estimates of population-level numbers in need to approximate the budget impact of equitably implementing the service.⁵⁸

Policy discussions on the integration of services to provide holistic care for patients requires economic evidence to support implementation in resource-limited contexts.^{4 23} By estimating the full economic costs of integrating the mental health treatment into the primary care offering for patients with chronic physical diseases, this study will provide much needed economic evidence to support this policy narrative.^{4 64 65} Empirical data on the costs of upskilling and training staff to deliver the intervention and the time costs of the alternative human resourcing strategies will also aid in understanding how this cadre of staff organise their work and may highlight opportunities for efficiency gains. This is timely in the current policy window where the idea of a 'facility counsellor' is being discussed, whose role may span a range of counselling duties including: adherence counselling for TB/HIV, chronic non-communicable physical diseases and mental health counselling. The integration of services is a key health systems focus⁶⁶ requiring economic evidence.²³ The integration of services at the primary care level⁶⁷ to manage communicable and non-communicable chronicity is a global challenge^{20 22 68 69} and a key strategic aim of the Department of Health⁷⁰ for expanding access to mental health services and managing chronic diseases in South Africa.^{27 70} Brief interventions for depression and alcohol use disorders lack a common outcome measure for use in CEA,⁷¹ thus limiting comparison across interventions.⁷² This study will provide unique cost-effectiveness evidence using the QALY as an outcome measure for such interventions in the South African context.⁵¹ This will allow comparability of cost-effectiveness results⁷³ and inform value for money decision making.^{48 74} This is of particular importance for South Africa as discussions around cost-effectiveness thresholds⁷⁴ are being increasingly presented in the health policy space in the prelude to National Health Insurance. This protocol also responds to the call to publish health economics protocols alongside trial protocols to reduce publication bias of randomised controlled trial results.⁷⁵

Potential challenges to this study include recall bias due to the reliance on patient-reported health service use for our estimations of service utilisation. To limit recall bias, a 1-month recall period will be used for ambulatory services and 6-month recall for hospitalisations.⁵² Another possible

limitation is that only a few patients may be referred for mental healthcare for CMD in the TAU option so we may not fully capture referral costs thus potentially underestimating cost-effectiveness. Another potential limitation is that the short follow-up period of 12 months may not capture the extent of the benefit that patients and the health system could gain through the availability of this service. For example, the degree to which the socioeconomic benefits and the returns to mental health associated with such interventions⁷⁶ may not be fully evident by the 12-month end point. This is a common problem associated with trial-based economic evaluations.⁷⁷

FUTURE WORK

Further work associated with this economic evaluation includes the use of modelling techniques to estimate the long-term benefits of the intervention both at the patient and system level and applying cost-benefit techniques to strengthen the evidence base for the mental health investment case.

CONCLUSION

Priority setting and decisions around the scale up of an integrated comprehensive primary care service need to be informed by micro-level and macro-level economic analyses of the investment requirements, impact and equity implications of delivering key services such as counselling. It is anticipated that the cost estimates, the CEA and budget impact analysis of this intervention will be a useful contribution to priority setting and policy making during the current reconfiguration of South Africa's health system.⁷⁸ It is hoped that the economic evaluation of project MIND will provide much needed evidence on the cost-effectiveness of integrating mental health services into primary care that could support a business case for investing in these services.

Author affiliations

¹Health Economics Unit, University of Cape Town School of Public Health and Family Medicine, Cape Town, Western Cape, South Africa

²Alcohol and Drug Abuse Research Unit, South African Medical Research Council, Tygerburg, Western Cape, South Africa

³Department of Psychiatry and Mental Health, Alan J Flisher Centre for Public Mental Health, University of Cape Town, Cape Town, Western Cape, South Africa

⁴Institute of Psychiatry, Psychology and Neuroscience, Health Services and Population Research, King's College London, London, UK

⁵Desmond Tutu HIV Research Centre, University of Cape Town School of Public Health and Family Medicine, Observatory, Western Cape, South Africa

⁶Western Cape Department of Health, Cape Town, Western Cape, South Africa

⁷Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Observatory, Western Cape, South Africa

Acknowledgements The authors would like to thank all WCDOH facilities, which have agreed to participate in the trial, and our Stakeholder Advisory Group for their contributions.

Contributors VM-M, SC and BM made substantial contributions to the conception and design of the study. The first draft of the manuscript was written by VM-M and critically revised by all authors for important intellectual content. All authors read and approved the final manuscript.

Funding This work is supported by the joint funded initiatives of the British Medical Research Council, Wellcome Trust and DFID (MR/M014290/1). BM is supported by the South African Medical Research Council.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the Western Cape Department of Health (WCDoH) (WC2016_RP6_9), the South African Medical Research Council (EC 004-2/2015), the University of Cape Town (089/2015) and Oxford University (OxTREC 2-17).

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

REFERENCES

- Patel V, Saxena S, Lund C, *et al*. The Lancet Commission on global mental health and sustainable development. *Lancet* 2018;392:1553–98.
- Whiteford HA, Degenhardt L, Rehm J, *et al*. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 2013;382:1575–86.
- Moussavi S, Chatterji S, Verdes E, *et al*. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007;370:851–8.
- Ngo VK, Rubinstein A, Ganju V, *et al*. Grand challenges: Integrating mental health care into the non-communicable disease agenda. *PLoS Med* 2013;10:e1001443.
- Vancampfort D, Mugisha J, Hallgren M, *et al*. The prevalence of diabetes mellitus type 2 in people with alcohol use disorders: a systematic review and large scale meta-analysis. *Psychiatry Res* 2016;246:394–400.
- Sorsdahl K, Sewpaul R, Evans M, *et al*. The association between psychological distress, alcohol use and physical non-communicable diseases in a nationally representative sample of South Africans. *J Health Psychol* 2018;23:618–28.
- Neuman MG, Schneider M, Nanau RM, *et al*. Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. *AIDS Res Treat* 2012;2012:1–14.
- Bernard C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. *PLoS One* 2017;12:e0181960.
- Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. *Diabetes Care* 2002;25:464–70.
- Katon WJ, Russo JE, Von Korff M, *et al*. Long-term effects on medical costs of improving depression outcomes in patients with depression and diabetes. *Diabetes Care* 2008;31:1155–9.
- Mayosi BM, Lawn JE, van Niekerk A, *et al*. Health in South Africa: changes and challenges since 2009. *Lancet* 2012;380:2029–43.
- Stein DJ, Seedat S, Herman A, *et al*. Lifetime prevalence of psychiatric disorders in South Africa. *Br J Psychiatry* 2008;192:112–7.
- Fulton BD, Scheffler RM, Sparkes SP, *et al*. Health workforce skill mix and task shifting in low income countries: a review of recent evidence. *Hum Resour Health* 2011;9:11.
- WHO. Treat, Train, Retain: Task Shifting Global Recommendations and Guidelines. *World Heal Organ* 2008;96.
- WHO. mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings Version 2.0. *mhGAP News* 2015;1:1–4.
- Joshi R, Alim M, Kengne AP, *et al*. Task shifting for non-communicable disease management in low and middle income countries—a systematic review. *PLoS One* 2014;9:e103754.
- Javadi D, Feldhaus I, Mancuso A, *et al*. Applying systems thinking to task shifting for mental health using lay providers: a review of the evidence. *Glob Ment Health* 2017;4:e14.
- Bruckner TA, Scheffler RM, Shen G, *et al*. The mental health workforce gap in low- and middle-income countries: a needs-based approach. *Bull World Health Organ* 2011;89:184–94.
- Mugisha J, De Hert M, Stubbs B, *et al*. Physical health policies and metabolic screening in mental health care systems of Sub Saharan african Countries: a s systematic review,. *Int J Ment Health Syst* 2017;1–7.
- Thornicroft G, Ahuja S, Barber S, *et al*. Integrated care for people with long-term mental and physical health conditions in low-income and middle-income countries. *Lancet Psychiatry* 2019;6:1–13.
- Haberer JE, Sabin L, Amico KR, *et al*. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. *J Int AIDS Soc* 2017;20:21371–15.
- Chuah FLH, Haldane VE, Cervero-Liceras F, *et al*. Interventions and approaches to integrating HIV and mental health services: a systematic review. *Health Policy Plan* 2017;32:iv27–iv47.
- Watson SI, Sahota H, Taylor CA, *et al*. Cost-effectiveness of health care service delivery interventions in low and middle income countries: a systematic review. *Glob Health Res Policy* 2018;3.
- Myers B, Lund C, Lombard C, *et al*. Comparing dedicated and designated models of integrating mental health into chronic disease care: study protocol for a cluster randomized controlled trial. *Trials* 2018;19:1–13.
- Lund C, Kleintjes S, Kakuma R, *et al*. Public sector mental health systems in South Africa: inter-provincial comparisons and policy implications. *Soc Psychiatry Psychiatr Epidemiol* 2010;45:393–404.
- Petersen I, Lund C. Mental health service delivery in South Africa from 2000 to 2010: One step forward, one step back,. *South African Med J* 2011;101:751–7.
- National Department of Health Republic of South Africa. National Mental Health Policy Framework and Strategic Plan 2013–2020. *Pretoria* 2013.
- Sorsdahl K, Myers B, Ward CL, *et al*. Adapting a blended motivational interviewing and problem-solving intervention to address risky substance use amongst South Africans. *Psychother Res* 2015;25:435–44.
- Myers B, Stein DJ, Mtukushe B, *et al*. Feasibility and Acceptability of Screening and Brief Interventions to Address Alcohol and Other Drug Use among Patients Presenting for Emergency Services in Cape Town, South Africa. *Adv Prev Med* 2012;2012:1–9.
- Sorsdahl K, Myers B, Ward C, *et al*. Screening and brief interventions for substance use in emergency departments in the Western Cape province of South Africa: views of health care professionals. *Int J Inj Contr Saf Promot* 2014;21:236–43.
- Sorsdahl K, Stein DJ, Corrigan J, *et al*. The efficacy of a blended motivational interviewing and problem solving therapy intervention to reduce substance use among patients presenting for emergency services in South Africa: A randomized controlled trial. *Subst Abuse Treat Prev Policy* 2015;10:1–10.
- Van Dam NT, Earleywine M. Validation of the Center for Epidemiologic Studies Depression Scale–Revised (CESD-R): pragmatic depression assessment in the general population. *Psychiatry Res* 2011;186:128–32.
- Babor TF, Higgins-Biddle JC, Saunders JB, *et al*. The Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care. *World Heal Organ* 2001:1–40.
- van Reenen M, Janssen B. EQ-5D-5L User Guide - Basic information on how to use the EQ-5D-5L instrument. Version 2.1, 2015.
- Hollingworth W, McKell-Redwood D, Hampson L, *et al*. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter? *Clin Trials* 2013;10:43–53.
- Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. *Pharmacoeconomics* 2018;36:745–58.
- Drummond MF, Sculpher MJ, Claxton K, *et al*. *Methods for the Economic Evaluation of Health Care Programmes*. 4th edn. Oxford: Oxford University Press, 2015.
- Jelsma J, Mkoka S, Amosun L, *et al*. The reliability and validity of the Xhosa version of the EQ-5D. *Disabil Rehabil* 2004;26:103–8.
- Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med* 2001;33:337–43.
- Kularatna S, Whitty JA, Johnson NW, *et al*. Health state valuation in low- and middle-income countries: a systematic review of the literature. *Value Health* 2013;16:1091–9.
- Brooke-Sumner C, Sorsdahl K, Lombard C, *et al*. Protocol for development and validation of a context-appropriate tool for assessing organisational readiness for change in primary health clinics in South Africa. *BMJ Open* 2018;8:e020539.
- Vassall A, Sweeney S, Kahn JG, *et al*. Reference Case for Estimating the Costs of Global Health Services and Interventions. *Global Health Cost Consortium* 2017.
- Naburi H, Ekström AM, Mujinja P, *et al*. The potential of task-shifting in scaling up services for prevention of mother-to-child transmission

- of HIV: a time and motion study in Dar es Salaam, Tanzania. *Hum Resour Health* 2017;15:35.
44. Odendaal WA, Lewin S. The provision of TB and HIV/AIDS treatment support by lay health workers in South Africa: a time-and-motion study. *Hum Resour Health* 2014;12:18.
 45. Foster N, Vassall A, Cleary S, et al. The economic burden of TB diagnosis and treatment in South Africa. *Soc Sci Med* 2015;130:42–50.
 46. Mauch V, Woods N, Kirubi B, et al. Assessing access barriers to tuberculosis care with the tool to Estimate Patients' Costs: pilot results from two districts in Kenya. *BMC Public Health* 2011;11:18–21.
 47. Huseareau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *Eur J Health Econ* 2013;14:367–72.
 48. Woods B, Revill P, Sculpher M, et al. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value Health* 2016;19:929–35.
 49. Gray AM, Wilkinson T. Economic evaluation of healthcare interventions: old and new directions: Table 1:. *Oxford Review of Economic Policy* 2016;32:102–21.
 50. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. *Health Econ* 2005;14:487–96.
 51. Dwommoh R, Sorsdahl K, Myers B, et al. Brief interventions to address substance use among patients presenting to emergency departments in resource poor settings : a cost – effectiveness analysis. *Cost Eff Resour Alloc* 2018;1–11.
 52. Hughes D, Charles J, Dawoud D, et al. Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. *Pharmacoeconomics* 2016;34:447–61.
 53. Carvalho N, Jit M, Cox S, et al. Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. *Pharmacoeconomics* 2018;36:79–90.
 54. Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges. *Eur J Health Econ* 2018;19:173–5.
 55. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. *Value Health* 2014;17:5–14.
 56. Stinnett AA, Paltiel AD. Allocation of Health Care Resources. *J Health Econ* 1996;15.
 57. Epstein DM, Chalabi Z, Claxton K, et al. Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. *Med Decis Mak* 2007;27(2):128–37.
 58. Cleary S, Mooney G, McIntyre D. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. *Health Econ* 2010;19:1166–80.
 59. Katon W, Russo J, Lin EH, et al. Cost-effectiveness of a multicondition collaborative care intervention. *Arch Gen Psychiatry* 2012;69(no. 5):506–14.
 60. Hay JW, Katon WJ, Ell K, et al. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. *Value Health* 2012;15:249–54.
 61. Richards DA, Hill JJ, Gask L, et al. Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. *BMJ* 2013;347(no. 14):f4913.
 62. Patel V, Chisholm D, Rabe-Hesketh S, et al. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. *Lancet* 2003;361(9351):33–9.
 63. Siskind D, Baingana FK, Kim J. Cost-Effectiveness of Group Psychotherapy Depression For Depression in Uganda. *J Ment Heal Policy Econ* 2008;11:127–33.
 64. Petersen I, Lund C, Bhana A, et al. A task shifting approach to primary mental health care for adults in South Africa: human resource requirements and costs for rural settings. *Health Policy Plan* 2012;27(1):42–51.
 65. Jack H, Wagner RG, Petersen I, et al. Closing the mental health treatment gap in South Africa: a review of costs and cost-effectiveness. *Glob Health Action* 2014;7:23431–11.
 66. Atun R, de Jongh T, Secci F, et al. Integration of targeted health interventions into health systems: a conceptual framework for analysis. *Health Policy Plan* 2010;25(2):104–11.
 67. Dudley L, Garner P. Strategies for integrating primary health services in low- and middle-income countries at the point of delivery. *Cochrane Database Syst Rev* 2011;2:CD003318.
 68. Haldane V, Legido-Quigley H, Chuah FLH, et al. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. *AIDS Care* 2018;30(1):103–15.
 69. Kemp CG, Weiner BJ, Sherr KH, et al. Implementation science for integration of HIV and non-communicable disease services in sub-Saharan Africa: a systematic review. *AIDS* 2018;32:S93–S105.
 70. Western Cape Government. *Healthcare 2030: The Road to Wellness*. Cape Town, 2014.
 71. Cowell AJ, Brown JM, Mills MJ, et al. Cost-effectiveness analysis of motivational interviewing with feedback to reduce drinking among a sample of college students. *J Stud Alcohol Drugs* 2012;73(2):226–37.
 72. Cowell AJ, Bray JW, Mills MJ, et al. Conducting economic evaluations of screening and brief intervention for hazardous drinking: Methods and evidence to date for informing policy. *Drug Alcohol Rev* 2010;29(6):623–30.
 73. Weinstein MC, Torrance G, McGuire A. QALYs: The Basics. *Value in Health* 2009;12:S5–S9.
 74. Thokala P, Ochalek J, Leech AA, et al. Cost-Effectiveness Thresholds: the Past, the Present and the Future. *Pharmacoeconomics* 2018;36:509–22.
 75. Powell-Jackson T, Davey C, Masset E, et al. Trials and tribulations: cross-learning from the practices of epidemiologists and economists in the evaluation of public health interventions. *Health Policy Plan* 2018;33:702–6.
 76. Lund C, Breen A, Flisher AJ, et al. Poverty and common mental disorders in low and middle income countries: A systematic review. *Soc Sci Med* 2010;71(3):517–28.
 77. Glick HA, Doshi JA, Sonnad SS, et al. *Economic Evaluation in Clinical Trials*. 2nd edn. New York: Oxford University Press, 2015.
 78. Rispel L, Moorman J, Chersich M, et al. *Revitalising Primary Health Care in South Africa: Review of primary health care package, norms and standards*. Johannesburg, 2010.